Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER3/topoisomerase I inhibitor antibody-drug conjugate DB-1310

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a maleimide tetrapeptide-based cleavable linker, to a cytotoxic DNA topoisomerase I inhibitor, with potential antineoplastic activity. Upon administration of anti-HER3 ADC DB-1310, the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells. Upon internalization, the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks, inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER3 ADC DB-1310
anti-HER3/topoisomerase I inhibitor ADC DB-1310
Code name:DB 1310
DB-1310
DB1310
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search